ASH 2021: Ivosidenib combined with azacitidine improves outcomes for newly diagnosed acute myeloid leukaemia with IDH-1 mutation compared with azacitidine alone
In a phase III trial, a combination of ivosidenib and azacitidine was found superior in…
Browsing: ivosidenib
ESMO 2019: First targeted therapy for cholangiocarcinoma shows clinical benefit in phase III trial
New data have shown for the first time that targeted therapy can improve the outcome…